[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360449-105":59,"doc-detail-360449-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","elevated-icam5-as-a-promising-predictor-of-poor-prognosis-in-bladder-cancer-via-emt-immune-microenvironment-and-therapy-resistance","Elevated ICAM5 as a promising predictor of poor prognosis in bladder cancer via EMT, immune microenvironment, and therapy resistance","","Bladder cancer is linked to poor outcomes driven by metastasis, invasion, and immune evasion, yet the role of intercellular adhesion molecule 5 (ICAM5) is not fully defined. Using TCGA and UCSC Xena data, this study evaluates ICAM5 expression, prognostic value, mutations, methylation, immune profiles, and regulatory functions. Results show ICAM5 is upregulated, correlates with advanced TNM and grades, remodels the immune microenvironment and immune checkpoints, and promotes EMT, proliferation, metastasis, and immunotherapy resistance.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/elevated-icam5-as-a-promising-predictor-of-poor-prognosis-in-bladder-cancer-via-emt-immune-microenvironment-and-therapy-resistance/360449/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/elevated-icam5-as-a-promising-predictor-of-poor-prognosis-in-bladder-cancer-via-emt-immune-microenvironment-and-therapy-resistance/360449.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main aim of this study on ICAM5 in bladder cancer?","Question",{"text":112,"@type":113},"To determine whether ICAM5 expression has prognostic significance and to clarify its roles in EMT, the immune microenvironment, and therapy resistance in bladder cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which databases and analytical approaches were used to study ICAM5?",{"text":117,"@type":113},"The study analyzed TCGA and UCSC Xena data, using WGCNA and Gene Set Cancer Analysis (GSCA) to explore ICAM5-related pathways and immune-related features.",{"name":119,"@type":110,"acceptedAnswer":120},"How does ICAM5 relate to prognosis and disease characteristics?",{"text":121,"@type":113},"ICAM5 expression was significantly upregulated and associated with advanced TNM stages, higher pathological grades, and more aggressive molecular subtypes.",{"name":123,"@type":110,"acceptedAnswer":124},"What mechanistic links were reported between ICAM5 and treatment resistance?",{"text":125,"@type":113},"ICAM5 was shown to promote epithelial-mesenchymal transition (EMT) and to modulate methylation and immune checkpoint expression, contributing to resistance to immunotherapy.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},360449,1790193972,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","OPEN ACCESS  \nCitation: Chen X, Wang Z, Rong Y, Zhu Z, Peng Z, Huang K, et al. (2026) Elevated ICAM5 as a promising predictor of poor prognosis in bladder cancer via EMT, immune microenvironment, and therapy resistance. PLoS One 21(6): e0347623. [https://doi](https://doi). org/10.1371/journal.pone.0347623  \nEditor: Zhengrui Li, Shanghai Jiao Tong University, CHINA  \nReceived: October 16, 2025  \nAccepted: April 5, 2026  \nPublished: June 8, 2026  \nCopyright: © 2026 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All the datasets analyzed in this study can be furtherly inquired here: TCGA, [https://portal.gdc.cancer.gov/](https://portal.gdc.cancer.gov/);WGCNA, [https://rdocumentation.org/packages/](https://rdocumentation.org/packages/)[ ](https://rdocumentation.org/packages/)[WGCNA/versions/1.72-5](WGCNA/versions/1.72-5); Kaplan-Meier Plotter, [http://kmplot.com/analysis/](http://kmplot.com/analysis/); GDC, [https://](https://)  \nRESEARCH ARTICLE  \nElevated ICAM5 as a promising predictor of poor prognosis in bladder cancer via EMT, immune microenvironment, and therapy resistance  \nXiaolong Chen1☯, Zhen Wang1☯, Yangsheng Rong2☯, Zhiqiang Zhu3, Zheng Peng3, Kunyuan Huang3, Guanyun Deng3, Di Liu4, Qing Wang1, Jianguo Zhu1*, Kun Chen5*, Kehua Jiang1*  \n1 Department of Urology, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, China, 2 Department of Urology, Weng’an County People’s Hospital, Guizhou, China, 3 Guizhou Medical University, Guiyang, Guizhou, China, 4 Department of Urology, People’s Hospital of Qiandongnan Miao and Dong Autonomous Prefecture, Kaili, 5 Department of Medical Genetics, Guizhou Provincial People’s Hospital, Guiyang, China  \n☯ These authors are contributed equally to this work.  \n* [tjjkh@sina.com](tjjkh@sina.com) (KHJ); [44844956@qq.com](44844956@qq.com) (KC); [doctorzhujianguo@163.com](doctorzhujianguo@163.com) (JGZ)  \nAbstract  \nBackground  \nBladder cancer, the most common malignancy of the urinary system, is associated with poor prognosis due to its metastatic potential, invasive behavior, and immune evasion. Intercellular adhesion molecule 5 (ICAM5), a member of the immunoglobulin superfamily, regulates cell adhesion and has been implicated in tumor progression. However, its biological function in bladder cancer remains unclear.  \nMethods  \nIn this study, we analyzed data from The Cancer Genome Atlas (TCGA) and UCSC Xena databases to investigate ICAM5 expression, prognostic significance, genetic mutations, methylation, immune profiles, and regulatory functions in bladder cancer. Weighted Gene Coexpression Network Analysis (WGCNA) and Gene Set Cancer Analysis (GSCA) were employed to explore ICAM5-related pathways.  \nResults  \nOur findings demonstrated that ICAM5 expression was significantly upregulated in bladder cancer and associated with advanced disease features, including higher TNM stages, pathological grades, and aggressive molecular subtypes. Furthermore, ICAM5 influenced the immune microenvironment, regulated methylation, and modulated immune checkpoint expression, contributing to immunotherapy resistance. Mechanistically, ICAM5 promoted epithelial-mesenchymal transition (EMT), proliferation, and metastasis.  \nPLOS One | [https://doi.org/10.1371/journal.pone.0347623](https://doi.org/10.1371/journal.pone.0347623) June 8, 2026 1 / 19  \n[portal.gdc.cancer.gov/](portal.gdc.cancer.gov/); GSCA, [http://bioinfo.life](http://bioinfo.life). [hust.edu.cn/GSCA/\\#/expression](hust.edu.cn/GSCA/#/expression);R 4 .1. 1, [http://](http://)[ ](http://)[www.r-project.org/](www.r-project.org/) .  \nFunding: This was supported by the National Natural Science Foundation of China (Grant No. 82060462, received by Kehua Jiang); the Science and Technology Fund Project of Guizhou Provincial He","cbCaiauBgTzhNeV0","https://ap.wps.com/l/cbCaiauBgTzhNeV0","pdf",2919283,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the main aim of this study on ICAM5 in bladder cancer?\",\"answer\":\"To determine whether ICAM5 expression has prognostic significance and to clarify its roles in EMT, the immune microenvironment, and therapy resistance in bladder cancer.\"},{\"question\":\"Which databases and analytical approaches were used to study ICAM5?\",\"answer\":\"The study analyzed TCGA and UCSC Xena data, using WGCNA and Gene Set Cancer Analysis (GSCA) to explore ICAM5-related pathways and immune-related features.\"},{\"question\":\"How does ICAM5 relate to prognosis and disease characteristics?\",\"answer\":\"ICAM5 expression was significantly upregulated and associated with advanced TNM stages, higher pathological grades, and more aggressive molecular subtypes.\"},{\"question\":\"What mechanistic links were reported between ICAM5 and treatment resistance?\",\"answer\":\"ICAM5 was shown to promote epithelial-mesenchymal transition (EMT) and to modulate methylation and immune checkpoint expression, contributing to resistance to immunotherapy.\"}]","Elevated ICAM5 as a promising predictor of poor prognosis in bladder cancer via EMT, immune microenvironment, and therapy resistance | PDF",1790140153,48,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf4f86cfd25c8ef26666e76e08e731c2.webp",983,1272,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/698e7f50784464a9a65cce6a15213d80.webp",982,1270,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c126622a7e601c2c5bb19f5fca1e9a91.webp",981,1269,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d82df6cad6c73a6da908fdba6bc9e4e6.webp",980,1268]